Salvage Focal Therapy Via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer
Focal One high intensity focused ultrasound device
Urogenital Diseases+7
+ Genital Diseases
+ Genital Diseases, Male
Treatment Study
Summary
Study start date: May 14, 2025
Actual date on which the first participant was enrolled.This study is investigating a treatment option called focal therapy using High Intensity Focused Ultrasound (HIFU) for men who have localized prostate cancer that has returned after radiation therapy. Typically, focal therapy is popular because it tends to have fewer side effects compared to more extensive treatments. HIFU has shown good results in patients with varying risks of prostate cancer, but there is not much information on its effectiveness for those whose cancer has returned after radiation. The researchers aim to gather more information about how well focal HIFU works in these cases, especially since many previous studies didn't use the latest imaging techniques which could help better identify and treat the cancer. In this study, participants will receive the focal HIFU treatment, which uses high-energy sound waves to target and destroy cancer cells in a specific area of the prostate without affecting the entire gland. The treatment is applied directly to the prostate and aims to minimize damage to surrounding healthy tissue. The study will evaluate both the cancer control and the impact on urinary and sexual function, as these are important considerations for patients. By focusing on how effective and safe focal HIFU is for treating recurrent prostate cancer, the study hopes to improve treatment options for those affected by this condition.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.25 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Male
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location